Early clearance of circulating hepatitis C virus enhanced by induction therapy with twice-a-day intravenous injection of IFN-β

Journal of Interferon and Cytokine Research

Volumn 20, Issue 9, 2000, Pages 831-836

  Ikeda, F ^a   Shimomura, H ^a   Miyake, M ^a   Fujioka, S I ^a   Itoh, M ^a   Takahashi, A ^a   Iwasaki, Y ^a   Sakaguchi, K ^a   Yamamoto, K ^a   Higashi, T ^a   Tsuji, T ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALANINE AMINOTRANSFERASE; BETA 2 MICROGLOBULIN; BETA INTERFERON; VIRUS RNA;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CLEARANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LONG TERM CARE; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS INFECTION;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INFUSIONS, INTRAVENOUS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0033800280     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/10799900050151102     Document Type: Article

References (28)

1. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report
2. Therapy of hepatitis C: Overview
3. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C
4. Factors predictive of a beneficial response to therapy of hepatitis C
5. Efficacy of the combination therapy using twice-a-day IFN-beta followed by IFN alpha-2b in treatment for chronic hepatitis C
6. Randomized control trial of interferon-beta injections at 12-h intervals as a therapy for chronic hepatitis C
7. Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection
8. Evaluation of twice-daily administration of interferon-beta for chronic hepatitis C
9. New Inuyama classification: New criteria for histological assessment of chronic hepatitis
10. Virological and serological characterization of asymptomatic blood donors positive for anti-hepatitis C virus antibody
11. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
12. Dynamics of hepatitis C viremia following interferon-alpha administration
13. Significance of early measurement of serum hepatitis C virus RNA in predicting response to interferon therapy in patients with chronic hepatitis C
14. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group
15. Interferon-alpha-2b and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: An Italian multicenter, randomized, controlled, clinical study
16. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT
17. Pharmacokinetics and biological effects of beta interferon by intravenous (iv) bolus administration in healthy volunteers as compared with iv infusion
18. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo
19. Type I interferons are essential mediators of apoptotic death in virally infected cells
20. A study of the interferon antiviral mechanism: Apoptosis activation by the 2-5A system
21. Activation of the IFN-inducible enzyme RNase L causes apoptosis of animal cells
22. Serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis B
23. Relationship of the effects of interferon on chronic hepatitis B and the induction of 2',5'-oligoadenylate synthetase
24. Induction of 2'-5' oligoadenylate synthetase during interferon treatment of chronic myelogenous leukemia
25. Effects of interferon on intrahepatic human leukocyte antigens and lymphocyte subsets in patients with chronic hepatitis B and C
26. Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon-alpha
27. Lymphocyte subsets and beta 2-microglobulin expression in chronic hepatitis C/non-A, non-B. Effects of interferon-alpha treatment
28. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level